Maintaining SYT13 protein levels in cells by targeting α-Syn oligomers could thus be a promising therapeutic avenue, with particular potential for the treatment of the cognitive impairment associated with synucleinopathies. This evidence concerns the gene SYT13 and synucleinopathy.